| 健保碼 | 註 | 藥品名稱 | 製藥廠 |
| A032116100 | 停用 | SERENIN S.C. TABLETS 10MG [OXAZOLAM] "EAYUNG" | 永吉製藥股份有限公司 |
| A032494100 | 停用 | FLUBEN S.C. TABLETS 40MG [FLURBIPROFEN] "EAYUNG" | 永吉製藥股份有限公司 |
| A0341711G0 | 停用 | FOAN CAPSULES 10MG [OXAZOLAM] "S.C"[鋁箔/膠箔] | 十全實業股份有限公司 |
| A038681100 | 停用 | DIMATAN TABLETS 80MG [GLICLAZIDE] "EAYUNG" | 仙台藥品工業股份有限公司 |
| A046116355 | 停用 | COLASA ENEMA 40MG/ML | 科進製藥科技股份有限公司 |
| AB49109100 | 停用 | BAENAZIN TABLETS 100 MG | 十全實業股份有限公司 |
| BC17664100 | 停用 | HYTRIN 2MG TABLETS | ABBVIE LTD |
| BC18878221 | 停用 | EBETREXAT 10MG/ML | |
| BC27219100 | 停用 | TROKENDI XR EXTENDED-RELEASE CAPSULES 25MG | CATALENT PHARMA SOLUTIONS IN |
| BC27220100 | 停用 | TROKENDI XR EXTENDED-RELEASE CAPSULES 50MG | CATALENT PHARMA SOLUTIONS IN |
| BC27221100 | 停用 | TROKENDI XR EXTENDED-RELEASE CAPSULES 100MG | CATALENT PHARMA SOLUTIONS IN |
| BC27222100 | 停用 | TROKENDI XR EXTENDED-RELEASE CAPSULES 200MG | CATALENT PHARMA SOLUTIONS IN |
| 健保碼 | 新價 | 藥品名稱 | 製藥廠 |
| AC59884157 | 565 | "晟德"康停懸液劑 | 晟德大藥廠股份有限公司新竹廠 |
| BC23291100 | 571 | GLIVEC CAPSULES 100MG | NOVARTIS PHARMA STEIN AG |
| BC24027100 | 571 | GLIVEC FILM-COATED TABLETS 100MG | NOVARTIS PHARMA PRODUKTIONS GM |
| BC24071100 | 541 | VALCYTE FILM-COATED TABLETS 450MG | PATHEON, INC. |
| BC24509248 | 998 | Mycamine for Injection 50mg/vial | ASTELLAS PHARMA TECH. CO., LTD |
| BC25360200 | 34117 | OZURDEX [DEXAMETHASONE INTRAVITREAL IMPLANT] 0.7MG | ALLERGAN PHARMACEUTICALS IRELA |
| BC25377414 | 350 | TAFLOTAN OPHTHALMIC SOLUTION | SANTEN PHARMACEUTICAL CO., LTD |
| BC26615405 | 15.2 | TAFLOTAN-S OPHTHALMIC SOLUTION | SANTEN PHARMACEUTICAL CO. LTD. |
| BC26714100 | 432 | Valgovir 450 F.C. Tablets | HETERO LABS LIMITED, UNIT V |
| BC26770405 | 17.7 | TAPCOM-S OPHTHALMIC SOLUTION | LABORATOIRE UNITHER |
| BC27327100 | 34539 | NINLARO CAPSULES 3 MG | HAUPT PHARMA AMAREG GMBH |
| BC27328100 | 45048 | NINLARO CAPSULES 4 MG | HAUPT PHARMA AMAREG GMBH |
| BC27592100 | 432 | VALGAN-450 [VALGANCICLOVIR TABLETS 450MG] | HETERO LABS LIMITED, UNIT V |
| BC27672457 | 1770 | TRIMBOW | CHIESI FARMACEUTICI S.P.A. |
| HCVDAA0002 | 2140 | VIEKIRAX + EXVIERA治療基因型1B型，無肝硬化或具代償性肝硬化12週療程 | FOURNIER LABORATORIES IRELAND |
| HCVDAA0003 | 2140 | VIEKIRAX + EXVIERA + RIBAVIRIN治療基因型1A型，無肝硬化12週療程 | FOURNIER LABORATORIES IRELAND |
| HCVDAA0004 | 1070 | VIEKIRAX + EXVIERA + RIBAVIRIN治療基因型1A型，代償性肝硬化24週療程 | FOURNIER LABORATORIES IRELAND |
| HCVDAA0005 | 2140 | ZEPATIER +/- RIBAVIRIN治療基因型1A型，無抗藥性病毒株，12週療程 | MSD International GmbH |
| HCVDAA0006 | 1605 | ZEPATIER + RIBAVIRIN治療基因型1A型，有抗藥性病毒株，16週療程 | MSD International GmbH |
| HCVDAA0007 | 2140 | ZEPATIER +/- RIBAVIRIN治療基因型1B型，12週療程 | MSD International GmbH |
| HCVDAA0008 | 2140 | ZEPATIER治療基因型第4型，12週療程 | MSD International GmbH |
| HCVDAA0009 | 1605 | ZEPATIER + RIBAVIRIN治療基因型第4型，16週療程 | MSD International GmbH |
| HCVDAA0012 | 3210 | MAVIRET治療基因型第1、2、3、4、5或6型，8週療程 | FOURNIER LABORATORIES IRELAND |
| HCVDAA0013 | 2140 | MAVIRET治療基因型第1、2、3、4、5或6型，12週療程 | FOURNIER LABORATORIES IRELAND |
| HCVDAA0014 | 1605 | MAVIRET治療基因型第1或3型，16週療程 | FOURNIER LABORATORIES IRELAND |
| KC01042299 | 21.4 | KOVALTRY INJECTION 1000 IU | BAYER HEALTHCARE LLC |
| KC01043299 | 21.4 | KOVALTRY INJECTION 500 IU | BAYER HEALTHCARE LLC |
| KC01044299 | 21.4 | KOVALTRY INJECTION 250 IU | BAYER HEALTHCARE LLC |
| KC01045299 | 21.4 | KOVALTRY INJECTION 2000 IU | BAYER HEALTHCARE LLC |
| KC01063209 | 30847 | TALTZ INJECTION | ELI LILLY AND COMPANY |
| KC01065221 | 38196 | Herceptin solution for injection | F. HOFFMANN-LA ROCHE LTD |
| KC01101209 | 67173 | FASENRA SOLUTION FOR INJECTION 30MG | CATALENT INDIANA, LLC |
| X000192100 | 22.7 | ZITHROMAX 250MG TABLETS | PFIZER AUSTRALIA PTY LIMITED |